Your browser doesn't support javascript.
loading
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Ellingson, Benjamin M; Patel, Kunal; Wang, Chencai; Raymond, Catalina; Brenner, Andrew; de Groot, John F; Butowski, Nicholas A; Zach, Leor; Campian, Jian L; Schlossman, Jacob; Rizvi, Shan; Cohen, Yael C; Lowenton-Spier, Noa; Minei, Tamar Rachmilewitz; Shmueli, Shifra Fain; Wen, Patrick Y; Cloughesy, Timothy F.
Affiliation
  • Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Patel K; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Wang C; UCLA Neuro Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Brenner A; Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • de Groot JF; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Butowski NA; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Zach L; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Campian JL; University of Texas Health San Antonio Cancer Center, San Antonio, Texas, USA.
  • Schlossman J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rizvi S; Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
  • Cohen YC; Oncology Institute, Chaim Sheba Medical Center, Tel HaShomer, Israel.
  • Lowenton-Spier N; Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Minei TR; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Shmueli SF; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Wen PY; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Cloughesy TF; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Neurooncol Adv ; 3(1): vdab082, 2021.
Article de En | MEDLINE | ID: mdl-34377989
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Prognostic_studies Langue: En Journal: Neurooncol Adv Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Prognostic_studies Langue: En Journal: Neurooncol Adv Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique